Cargando…
IL-38: A New Player in Inflammatory Autoimmune Disorders
Interleukin (IL)-38, a newly discovered IL-1 family cytokine, is expressed in several tissues and secreted by various cells. IL-38 has recently been reported to exert an anti-inflammatory function by binding to several receptors, including interleukin-36 receptor (IL-36R), interleukin-1 receptor acc...
Autores principales: | Xie, Lihui, Huang, Zhaohao, Li, He, Liu, Xiuxing, Zheng, Song Guo, Su, Wenru |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6723600/ https://www.ncbi.nlm.nih.gov/pubmed/31387327 http://dx.doi.org/10.3390/biom9080345 |
Ejemplares similares
-
Therapeutic Effect of IL-38 on Experimental Autoimmune Uveitis: Reprogrammed Immune Cell Landscape and Reduced Th17 Cell Pathogenicity
por: Li, He, et al.
Publicado: (2021) -
Adalimumab in Vogt-Koyanagi-Harada Disease Refractory to Conventional Therapy
por: Yang, Shizhao, et al.
Publicado: (2022) -
Pharmacological Inhibition of Caspase-8 Suppresses Inflammation-Induced Angiogenesis in the Cornea
por: Tian, Yunzhe, et al.
Publicado: (2020) -
The Efficacy of Adalimumab as an Initial Treatment in Patients with Behçet’s Retinal Vasculitis
por: Yang, Shizhao, et al.
Publicado: (2021) -
Systemic glucocorticoid-free therapy with adalimumab plus immunosuppressants versus conventional therapy in treatment-naïve Vogt-Koyanagi-Harada disease patients
por: Yang, Shizhao, et al.
Publicado: (2022)